Biotest
Biotest AG, a leading player in the biopharmaceutical industry, is headquartered in Dreieich, Germany. Founded in 1946, the company has established itself as a pioneer in the development and production of immunoglobulins and blood plasma products. With a strong focus on therapeutic areas such as immunology and haematology, Biotest is committed to enhancing patient care through innovative solutions. The company’s core offerings include high-quality plasma-derived therapies, which are distinguished by their rigorous quality standards and advanced manufacturing processes. Biotest has achieved significant milestones, including the expansion of its global presence, with operations spanning Europe, North America, and Asia. Renowned for its commitment to research and development, Biotest continues to solidify its market position as a trusted provider of essential biopharmaceuticals, contributing to improved health outcomes worldwide.
DitchCarbon Score
How does Biotest's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Health Services industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Biotest's score of 22 is higher than 89% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Biotest's reported carbon emissions
In 2022, Biotest reported total carbon emissions of approximately 19,116,100 kg CO2e, which includes about 18,185,600 kg CO2e from Scope 1 emissions and around 930,500 kg CO2e from Scope 2 emissions. This marks a significant reduction from previous years, particularly from 2021, when total emissions were about 2,054,400 kg CO2e. Biotest has demonstrated a commitment to reducing its carbon footprint, although specific reduction targets or initiatives have not been disclosed. The company has consistently reported emissions data, focusing on Scope 1 and Scope 2 emissions, which are critical for understanding its direct and indirect environmental impact. As a leader in the biopharmaceutical industry, Biotest's efforts align with broader climate commitments, reflecting an awareness of the importance of sustainability in corporate practices. The company continues to monitor and report its emissions, contributing to transparency and accountability in its climate strategy.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2018 | 2021 | 2022 | |
|---|---|---|---|
| Scope 1 | 893,000 | 0,000,000 | 00,000,000 |
| Scope 2 | 16,537,200 | 000,000 | 000,000 |
| Scope 3 | - | - | - |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Biotest is not committed to any reduction initiatives we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
